Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing.

Mounjaro's launch of a weight-loss drug has sparked interest amongst the people of India despite the high price. Experts believe that making the drug locally available would help to reduce the black ...

Pfizer had intended to move the drug into late-stage testing, but called it quits after a patient in a clinical trial experienced a potentially drug-related liver injury. View on euronews ...